Health Care • Biotechnology: Pharmaceutical Preparations
$41.47 ▲ +1.50
(+3.75%)
MKT CAP: $48.32B • VOL: 5.23M
52W L $20 52W H $43
TEVA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $17.26B | $16.54B | $15.85B |
| YoY Revenue Growth % | +4.3% | +4.4% | — |
| Gross Profit | $8.94B | $8.06B | $6.97B |
| Gross Margin % | 51.8% | 48.7% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $2.16B | -$303.0M | $433.0M |
| Operating Margin % | 12.5% | -1.8% | 2.7% |
| Net Income (GAAP) | $1.41B | -$1.64B | -$559.0M |
| EBITDA (Normalized) | $2.78B | $292.6M | $1.00B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.65B | $1.25B | $1.37B |
| Capital Expenditures (CapEx) | $776.6M | $744.5M | $713.1M |
| Free Cash Flow (FCF) | $872.4M | $502.5M | $654.9M |
| FCF Margin % | 5.1% | 3.0% | 4.1% |
| Return on Invested Capital (ROIC %) | 8.9% | -1.4% | 2.1% |
| Cash & Short-Term Equivalents | $3.56B | $3.30B | $2.92B |
| Total Debt (Short + Long Term) | $14.78B | $15.12B | $6.22B |
| Total Stockholders' Equity | $7.91B | $5.37B | $12.76B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TEVA.